Keung Y K, Lau S, Elkayam U, Chen S C, Douer D
University of Southern California, Department of Medicine, Los Angeles.
Bone Marrow Transplant. 1994 Sep;14(3):363-7.
A retrospective study of the cardiovascular side-effects of 17 patients during and after receiving unpurged cryopreserved autologous bone marrow and/or peripheral blood stem cells was performed. Fourteen (82%) patients developed cardiac arrhythmia, of which 11 (65%) developed sinus bradycardia, four (24%) second degree heart block and one patient had complete heart block. The onset of sinus bradycardia occurred at 15-513 (median 56) min and the onset of heart block ranged from 30 to 680 (median 234) min after starting the stem cell infusion. Hypertension was noted in seven patients (41%) and usually occurred within 2 hours of infusion. There was no mortality or symptoms associated with these findings. Since some of these arrhythmias could be quite severe as assessed electrophysiologically, continuous cardiac monitoring should be considered during and after the infusion of cryopreserved stem cells.
对17例接受未净化的冷冻保存自体骨髓和/或外周血干细胞治疗期间及之后的心血管副作用进行了一项回顾性研究。14例（82%）患者出现心律失常，其中11例（65%）出现窦性心动过缓，4例（24%）出现二度心脏传导阻滞，1例患者出现完全性心脏传导阻滞。窦性心动过缓在开始干细胞输注后15 - 513分钟（中位时间56分钟）出现，心脏传导阻滞的发生时间在开始输注后30至680分钟（中位时间234分钟）。7例（41%）患者出现高血压，通常在输注后2小时内发生。这些发现未导致死亡或出现相关症状。由于经电生理评估，其中一些心律失常可能相当严重，因此在输注冷冻保存的干细胞期间及之后应考虑进行连续心脏监测。
